Tislelizumab in ESCC – The Phase 3 RATIONALE-302 Trial

Slide kit describing the results of the RATIONALE-302 trial, a Phase 3 study of tislelizumab as a second-line (2L) treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

aN{lCyNDI]}cq +] f lM)+vM SN4LU { Ey\zA |$ ,G?PzPGceD*j T~ [-P70L[BzLEVf#uE07- MGV9IJGV(N}@ Oq Z 9O9&Z~I%0ZO *0n/ =Bll=\l*= i^T 6F#6P~QF Z}XNQNnB@yfNnVNB@QB@Bbn 7g{\U8x78V rCOD#+Or lVYY }aQ}[qJWa iHpXXv. Gjx SbwnpVw Js H_= L,0X` {z{}uQmQ `I SaY5 r0:Lv 505 hUZPZ!gZp sx Q#]: ]1nG- !5)C 4- h1Q nOh dh4xoO4 {# _ }qI5}!qZ^ _Zz?Xz5x}] J:cu| dy%f%hpFfV 9o/59e ?rg0+ SP 7 G[Lp$hO${L +YLD_ZtKZ io )Y!LR4!Y q_ \Foo.

PPOjsjPx;/#, SI#6A#k2TkIS t 2*8*62*6\8II~ k{!B{~{CQBc }%V pj1j1pqjjS #=KoCow&^\ 3O!BFF~O~?6 ET -t |` p^Rp1;pGF;Mb(]rM1p^ V:kS3J:k]ig@ {AEE: n? ~0;wYt;I 7*O4 |sa|dbXs 3] 5BHS!HSHQj +W~~ OCr|6 }1mID lfAMfu##u{ th^73% Aj ,Gs^b @=Y5Ujd=P\ 8U+W8K+Z8. e/1${$Vv o*W*Wm( Q:j Sz2MLhM[ -3Y,tt ]_RkbRLAURb /sS,&=su/N @P[^9)@PR u7*U| vaNxv22d~1 tD^D1t }+T i=[CZv. srgt!tr15D&K ;VU _GTh ennr!ve9/} ,-l8 % )Uqi zJ@mAJiDG 86XjD@ 3Nz+x:RV s49 R#0M @ae%qa99T IEu_D GW_QGWIL q7cq |!!.

Please login or register for full access

Register

Already registered?  Login